Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial - Ruiz Seco, Maria Pilar; Paño Pardo, José Ramón; Schoergenhofer, Christian; Dings, Christiane; Lehr, Thorsten; Herth, Felix; Krendyukov, Andriy; Straub, Carola; Kappler, Martin; Jilma, Bernd; Fricke, Harald; Pardo, Julian; et al. (EClinicalMedicine, 2024)
Online verfügbar: 24. Oktober 2024